September 2026 Research Update

Across these studies, a step-by-step genetic testing approach helped explain the cause of ataxia for many people, but the most common genetic answers differed by region and by age group. Repeat expansions were a major source of diagnoses in adults, while childhood-onset hereditary ataxia more often involved non-repeat (single-gene) conditions that were found using gene panels or whole-exome sequencing. Together, the papers suggest that the best first test can depend on the local genetic landscape and the clinical situation. [1] [2] [3] [4]

In a large Chinese cohort of 2,096 people with hereditary ataxia, most genetic diagnoses were due to a small number of repeat-expansion types, with one subtype (SCA3) making up more than half of all probands. Using a repeat-expansion focused workflow found most diagnoses, and broader sequencing (gene panels or whole-exome sequencing) provided additional diagnoses for a smaller group, supporting a strategy that starts with the most common repeat expansions in that region before moving to broader testing. [1]

In New Zealand adults with idiopathic late-onset cerebellar ataxia, an updated repeat-expansion panel that included the FGF14 gene found SCA27B in 9 of 29 tested people. In this small cohort, SCA27B often started in midlife and could begin in episodes, and imaging sometimes showed cerebellar shrinkage or a specific brainstem-related sign on MRI. [3]

In a single Argentinean patient, an FGF14 repeat expansion (SCA27B) was found after the condition had initially been labeled as alcohol-related cerebellar damage, illustrating how genetic testing can change the explanation for symptoms in some individuals. Because this is one person, it cannot show how often this mislabeling happens, but it highlights that SCA27B can look like other adult-onset ataxias. [4]

In a single-center pediatric cohort in Oman, most hereditary ataxia cases were autosomal recessive, and ataxia telangiectasia was the most common diagnosis. Genetic testing had a high confirmation rate among those tested, with gene panels and whole-exome sequencing both contributing; MRI often showed cerebellar shrinkage. The authors also noted that molecular diagnosis identified a small number of cases with a specific genetic cause (COQ10D4) where supplementation was reported to help, emphasizing why pinpointing the genetic type can matter. [2]

For patients and caregivers, these studies mainly add context about why genetic testing is often done in steps rather than as a single test. They show that many adult ataxias can be explained by repeat expansions (including FGF14 in late-onset cases), while many childhood cases may require gene panels or whole-exome sequencing to find the cause. What remains uncertain is how well any one region's testing pathway applies elsewhere, since the most common genetic types differed markedly between the Chinese and Omani cohorts, and the FGF14 results come from small adult samples and a single case report.

Across these reports, spinocerebellar ataxia sometimes appeared in ways that did not match the classic picture of mainly balance and coordination problems. Several people had prominent movement symptoms (chorea or parkinsonism), early cognitive or developmental difficulties, or eye-movement symptoms even before clear ataxia, and genetic testing helped connect these presentations to specific ataxia-related genes. Most evidence here comes from single-patient case reports, so the full range and frequency of these symptoms remains uncertain. [5] [6] [7] [8] [9]

One report described spinocerebellar ataxia type 34 features in a 35-year-old man with early severe cognitive decline and parkinsonism, along with brain scans showing cerebellar and more widespread shrinkage. A previously unreported ELOVL4 frameshift variant was found, but it was not confirmed with additional lab methods or family testing, so whether it is truly disease-causing still needs more proof. Over 1 year, he reported mild improvement in tremor, gait difficulty, and stiffness, while speech problems and constipation worsened. [5]

Another case showed that adult-onset chorea can, in some situations, be part of spinocerebellar ataxia type 5 rather than Huntington's disease. In a 51-year-old man, whole-exome sequencing found a novel SPTBN2 variant, and the family pattern across three generations supported it as the likely cause; brain imaging showed cerebellar shrinkage. Over 9 months, chorea improved while cerebellar signs stayed stable. [6]

A different report highlighted that noticeable eye-movement symptoms may come before obvious incoordination in some genetic ataxias. A 23-year-old woman had dizziness and downbeat nystagmus without clear cerebellar ataxia on exam, even though MRI showed severe cerebellar shrinkage; genetic testing found ANO10 variants consistent with autosomal-recessive spinocerebellar ataxia type 10. The authors described this as a clinicoradiological mismatch, meaning scans looked advanced compared with the bedside exam. [7]

Two identical twins expanded what has been described for spinocerebellar ataxia type 19/22 by combining early-onset ataxia with developmental delay and severe intellectual disability. They had a de novo KCND3 p.L368P variant, and lab testing showed the altered potassium channel produced no measurable current and also interfered with the normal channel, helping explain why symptoms could be severe. MRI showed cerebellar shrinkage with flattening of part of the brainstem. [8]

One case raised questions about overlap between ataxia and motor neuron disease. A 66-year-old woman with bulbar-onset amyotrophic lateral sclerosis (ALS) also had cerebellar ataxia and an intermediate-length CACNA1A repeat; her son had the same type of intermediate repeat and isolated ataxia. The report emphasized that the meaning of intermediate-length CACNA1A repeats in ALS is still uncertain, and the case alone cannot show cause and effect. [9]

For patients and caregivers, these papers mainly provide context: ataxia-related gene changes can sometimes show up with unexpected symptoms (for example, chorea, parkinsonism, eye-movement problems, developmental differences, or possible overlap with ALS), and genetic testing may help sort out confusing diagnoses. However, most evidence here is from single families or single individuals, so it is not clear how often these patterns occur or whether every newly reported variant truly causes disease. Some reports include lab experiments that strengthen the link between a specific variant and symptoms, but for several newly described variants, additional confirmation in families and further studies are still needed.

Across these studies, research on symptom treatment in spinocerebellar ataxia (SCA) included one moderate-sized randomized trial and two smaller exploratory reports. Results pointed to modest improvement in movement-based ataxia scores with one oral medicine in SCA type 3, while another trial focusing on a blood marker showed mixed results, and a single-patient report described benefit for parkinsonism symptoms in SCA type 8. [10] [11] [12]

In a randomized, placebo-controlled trial in 116 people with SCA type 3, oral DL-3-n-butylphthalide (NBP) led to greater improvement over 12 months on standard ataxia rating scales than placebo. No serious adverse events were reported, and overall side effects were similar between groups, suggesting the treatment was generally tolerated in this study. [10]

In a smaller triple-blind crossover trial in SCA type 3, Astragalus membranaceus was tested for 12 weeks and the main outcome was a blood marker linked to nerve cell injury (neurofilament light). The marker went down slightly during the Astragalus period, but the adjusted difference versus placebo was not statistically significant, so the study did not confirm a clear treatment effect on this biomarker. Safety results were described as acceptable, with mild side effects similar to placebo. [11]

A separate case report described one 27-year-old man with SCA type 8 who had early-onset parkinsonism and trouble with wearing-off and involuntary movements on oral levodopa. After switching to continuous under-the-skin infusion of foscarbidopa/foslevodopa, his movement scores improved markedly in the "on" state; because this is a single patient, it is not known how often similar benefit occurs in others with SCA type 8 or related symptoms. [12]

For patients and caregivers, these papers mainly add to the evidence base about symptom-targeted treatments in specific SCA types, rather than establishing a standard approach. The NBP study in SCA type 3 is the strongest evidence here because it was randomized and followed people for 12 months, but the size of the improvement and how well it translates to day-to-day function still needs more clarification. The Astragalus study is best viewed as early-stage research because it was small and did not show a clear difference versus placebo on its main blood test outcome. The infusion report is important background for people with SCA type 8 who also develop parkinsonism features, but it represents one individual and cannot predict typical results or risks. [10] [11] [12]

Across these studies, researchers tested three different kinds of tracking tools for spinocerebellar ataxia (SCA): a patient-reported symptom questionnaire, wearable balance measurements, and a blood-based metabolic pattern test. Overall, the work suggests these tools can capture differences between people with SCA and healthy controls, but short-term (1-year) change can be small and variable, and some tools are still at an early, single-center stage. [13] [14] [15]

In a Dutch longitudinal cohort including SCA1, SCA3, and SCA7, PROM-Ataxia (a patient questionnaire about ataxia symptoms and daily function) lined up well with several established clinical scales and quality-of-life measures, supporting that it is measuring related aspects of disease. It also separated some people in very early (pre-ataxic) stages from healthy controls, suggesting it may detect symptoms before clear changes show up on traditional exam-based scores. Over one year, the average PROM-Ataxia total score increased by 3.9 points, but responses varied widely between individuals, and the study estimated a larger change was needed to count as a meaningful within-person change. [13]

For SCA3 specifically, one study used pressure-sensing insoles during standing to capture balance signals (center of pressure patterns). Measures taken while standing with eyes closed separated SCA3 participants from healthy controls better than eyes-open measures, and several balance variables correlated with clinical severity scores. A machine-learning model using these insole signals classified severity groups with 87% accuracy in this dataset, and interpretability analyses highlighted which balance features contributed most. [14]

Another single-center study explored a blood test approach for SCA3 based on a plasma metabolic fingerprint measured by mass spectrometry and analyzed with a classifier. In this retrospective dataset of 202 participants, the full metabolic fingerprint model showed high classification performance in both a discovery set (AUC 0.952) and an internal time-based validation set (AUC 0.963). A smaller panel of 21 metabolites performed less well but still showed high AUCs (0.901 and 0.932), and exploratory analyses were used to add biological context to the metabolic patterns. [15]

Right now, these studies mainly add to how researchers may measure SCA in clinics and trials rather than changing everyday care. A questionnaire like PROM-Ataxia may help capture symptoms and daily-life impact that are not fully reflected in exam-based scores, but the average 1-year change was small and varied a lot between people. Wearable balance sensing and blood metabolic pattern testing for SCA3 could eventually support tracking or classification, but both were tested in single-center research settings and need broader validation to understand accuracy, consistency over time, and how results should be interpreted for individuals. [13] [14] [15]

Across this multisite MRI study, SCA27B was linked to a recognizable set of changes in the cerebellum, brain white matter, and the cervical (neck) spinal cord. The overall pattern points to SCA27B affecting more than the cerebellum alone, although the study design cannot show how these changes develop over time. [16]

The clearest structural change was shrinkage (atrophy) in the cerebellar vermis, the midline part of the cerebellum important for balance and coordination. The atrophy was reported in specific vermis areas (lobules I to IV and vermis VIII), suggesting a more focused regional pattern rather than uniform cerebellar loss. [16]

MRI measures sensitive to tissue microstructure showed widespread differences in subcortical brain white matter compared with matched healthy controls. In plain language, this kind of change can mean the wiring that connects brain areas may be affected, even when shrinkage is not the main feature being measured. [16]

The study also measured the cervical spinal cord and found reduced gray matter area while white matter area was preserved. This suggests that, at least on these MRI measures, certain spinal cord structures may be more affected than others in SCA27B. [16]

For patients and caregivers, this research mainly adds background about what MRI can show in SCA27B and how it may differ from healthy brains and spinal cords. Because this was a cross-sectional study (a snapshot in time), it does not tell whether these MRI changes predict future symptoms or how quickly they progress, but it helps define imaging features that could be used in future natural history studies or research trials. [16]

Across this research, a consistent message is that spinocerebellar ataxia (SCA) can affect more than balance and coordination. In adults with adult-onset cerebellar ataxia seen in a specialist clinic, mood symptoms, cognitive (thinking) changes, and pain were frequently documented, with mood symptoms standing out as especially common in people with SCA. [17]

In a retrospective review of 145 adults with adult-onset cerebellar ataxia, mood disorders were the most commonly recorded non-motor symptom (28.9%), followed by cognitive impairment (24.1%) and pain (18.6%). This means that in real-world clinic care, non-motor symptoms may be a noticeable part of the overall condition for many people. [17]

Depression or anxiety was documented more often in the SCA group than in non-SCA ataxias (41.5% vs 23.9%). The study also reported that depression or anxiety was more common in those diagnosed at a younger age, based on a small negative correlation with age at diagnosis. [17]

For patients and caregivers, these results add context that SCA is often discussed as a movement problem, but mood symptoms, thinking changes, and pain may also be part of the day-to-day experience for some people. Because this was a chart review from a tertiary clinic, it mainly reflects what was recognized and recorded in that setting, and it cannot show how often these issues occur in the wider SCA community or what causes them.

Across two preclinical studies, a consistent pattern was that expanded ataxin-3 can disrupt basic cell housekeeping in nerve cells, including how misfolded proteins clump together and how mitochondria support energy needs. [18] [19] These studies suggest nerve damage in SCA3 may come from multiple stress pathways acting at the same time, rather than a single problem. [18] [19]

One study identified Importin-8 (IPO8) as a regulator of ataxin-3 aggregation: lowering IPO8 reduced ataxin-3 clumps in cells and in mouse brain regions affected in SCA3 models, while increasing IPO8 made clumping worse. [18] In mice, lowering IPO8 was also linked to less nerve cell injury on brain tissue measures and better performance on movement tests, without changing where ataxin-3 was located inside the cell. [18]

The same IPO8 study connected these changes to shifts in cell signaling: lowering IPO8 decreased levels of NF-kB/p65 signaling (including nuclear phosphorylated NF-kB/p65) and increased Ago2, which is involved in how cells use small RNAs to regulate proteins. [18] The authors noted that the exact cause-and-effect links between IPO8, these signaling pathways, and ataxin-3 aggregation still need clarification. [18]

A second study focused on mitochondria, the parts of cells that help produce energy, and found mitochondrial dysregulation across multiple SCA3 models (mice, zebrafish, and primary neurons). [19] Changes repeatedly involved proteins tied to oxidative phosphorylation and especially complex II of the mitochondrial electron transport chain, and the zebrafish model showed increased sensitivity to the mitochondrial toxin rotenone. [19]

For patients and caregivers, these results mainly add background about why nerve cells may become injured in SCA3: misfolded ataxin-3 protein can form clumps, and cells may also struggle with energy production and stress signaling. [18] [19] Because these are cell and animal studies, they do not show how strongly these processes drive symptoms in people or whether changing them would translate into a useful therapy. [18] [19] The key uncertainties are which pathways matter most in human SCA3 and whether targets like IPO8, NF-kB-related signaling, Ago2-related regulation, or mitochondrial complex II changes are causes of nerve damage or downstream effects. [18] [19]

One human genetic study showed that, in some inherited ataxias, additional repeat expansions can act like a volume knob that shifts when symptoms begin, even if they do not clearly change the type of symptoms. [20] This work was in STUB1-related ataxia (SCA48 and SCAR16), so it does not directly test modifiers in SCA3, but it supports the broader idea that nerve damage risk in ataxia can be influenced by more than one genetic factor. [20]

Among 67 people with a single (monoallelic) STUB1 variant, 7 had intermediate ATXN8OS expansions, and this subgroup had earlier symptom onset (median 28 years) than other SCA48 individuals without the expansion (median 47 years). [20] The study reported no major differences in the overall clinical picture beyond earlier onset, meaning the expansion seemed to shift timing more than symptom type in this cohort. [20]

ATXN8OS expansions were also found in a small fraction of healthy controls over age 50 and in some people with autosomal-dominant ataxia of other causes, which suggests these expansions do not always lead to disease by themselves. [20] The authors proposed that ATXN8OS expansions could increase nerve cell stress (for example through RNA foci and effects on STUB1 protein quality-control activity), but this mechanism was not directly proven in this study. [20]

This study matters now mostly for understanding why age at onset can vary widely across people and families with inherited ataxia, and it highlights that extra genetic factors may influence nerve cell vulnerability. [20] However, the results were specific to STUB1-related ataxia and did not evaluate people with SCA3, so it should be viewed as indirect context for the question of nerve damage in SCA3. [20] Uncertainties include how often similar genetic modifiers affect SCA3 and how strongly they would change symptoms or progression in an individual person. [20]